Published in Arthritis Res Ther on June 10, 2005
Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study. Arthritis Res Ther (2009) 1.44
Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. J Exp Med (2010) 1.02
Spontaneous autoimmunity in mice that carry an IghV partial transgene: a required arginine in VHCDR3. Lupus (2009) 0.85
Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in hemostasis. Arthritis Rheum (2011) 0.77
An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J Exp Med (1970) 9.83
Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity. Proc Natl Acad Sci U S A (1980) 7.84
Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum (1990) 3.37
Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis. J Clin Invest (1977) 2.66
Genetic and structural evidence for antigen selection of anti-DNA antibodies. Annu Rev Immunol (1994) 2.45
Residues that mediate DNA binding of autoimmune antibodies. J Immunol (1993) 2.37
Antibody-antigen interactions: contact analysis and binding site topography. J Mol Biol (1996) 2.22
Murine monoclonal anti-DNA antibodies bind directly to glomerular antigens and form immune deposits. J Immunol (1987) 2.09
Anti-DNA antibodies bind directly to renal antigens and induce kidney dysfunction in the isolated perfused rat kidney. J Immunol (1989) 1.86
Chromatin specificity of anti-double-stranded DNA antibodies and a role for Arg residues in the third complementarity-determining region of the heavy chain. J Immunol (2003) 1.70
Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int (1995) 1.63
Deletion and editing of B cells that express antibodies to DNA. J Immunol (1994) 1.62
Histone acetyltransferases: preparation of substrates and assay procedures. Methods Enzymol (1999) 1.61
Peptide inhibition of glomerular deposition of an anti-DNA antibody. Proc Natl Acad Sci U S A (1997) 1.61
Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J Clin Invest (1994) 1.54
Mutational analysis of an autoantibody: differential binding and pathogenicity. J Exp Med (1994) 1.53
Alpha-actinin is a cross-reactive renal target for pathogenic anti-DNA antibodies. J Immunol (2002) 1.49
Detection of cross-reactive anti-DNA antibody idiotypes in the serum of systemic lupus erythematosus patients and of their relatives. Arthritis Rheum (1985) 1.48
Lupus anti-DNA autoantibodies cross-react with a glomerular structural protein: a case for tissue injury by molecular mimicry. Eur J Immunol (2001) 1.46
Co-localization of nephrin, podocin, and the actin cytoskeleton: evidence for a role in podocyte foot process formation. Am J Pathol (2002) 1.34
Significance of enzyme linked immunosorbent assay (ELISA) for antibodies to double stranded and single stranded DNA in patients with lupus nephritis: correlation with severity of renal histology. Ann Rheum Dis (1993) 1.16
Structure-function analysis of a lupus anti-DNA autoantibody: central role of the heavy chain complementarity-determining region 3 Arg in binding of double- and single-stranded DNA. Eur J Immunol (2000) 1.06
Genetic, structural and functional properties of an IgG DNA-binding monoclonal antibody from a lupus patient with nephritis. Eur J Immunol (1998) 1.00
Antigen specificity of anti-nuclear antibodies complexed to nucleosomes determines glomerular basement membrane binding in vivo. Eur J Immunol (1997) 0.95
The importance of somatic mutations in the V(lambda) gene 2a2 in human monoclonal anti-DNA antibodies. J Mol Biol (2001) 0.93
Serological and genetic characterization of a human monoclonal immunoglobulin G anti-DNA idiotype. J Clin Invest (1994) 0.89
Structural elements controlling anti-DNA antibody affinity and their relationship to anti-phosphorylcholine activity. J Immunol (1996) 0.87
Properties of whole human IgG molecules produced by the expression of cloned anti-DNA antibody cDNA in mammalian cells. J Autoimmun (1998) 0.86
Functional and modelling studies of the binding of human monoclonal anti-DNA antibodies to DNA. Mol Immunol (1996) 0.86
Systematic analysis of sequences of anti-DNA antibodies--relevance to theories of origin and pathogenicity. Lupus (2002) 0.85
Production and analysis of IgG monoclonal anti-DNA antibodies from systemic lupus erythematosus (SLE) patients. Clin Exp Immunol (1993) 0.84
Immunopathogenesis of SLE. Baillieres Clin Rheumatol (1998) 0.83
Somatic mutations to arginine residues affect the binding of human monoclonal antibodies to DNA, histones, SmD and Ro antigen. Mol Immunol (2004) 0.82
Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science (2004) 15.91
Systemic lupus erythematosus. N Engl J Med (2008) 10.22
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum (2012) 6.85
Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med (2004) 6.48
CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity (2010) 5.13
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum (2010) 4.57
Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum (2013) 4.02
PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. Mol Cell (2009) 3.17
An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum (2002) 2.54
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis (2012) 2.21
A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum (2009) 2.19
Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. Clin Cancer Res (2005) 1.99
Rhubarb and reliability -- a Jane Austen view of systemic lupus erythematosus. J Rheumatol (2013) 1.98
Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet (2003) 1.98
Maternal cadmium exposure during pregnancy and size at birth: a prospective cohort study. Environ Health Perspect (2011) 1.94
Altered cleavage and localization of PINK1 to aggresomes in the presence of proteasomal stress. J Neurochem (2006) 1.91
CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med (2013) 1.89
Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology (Oxford) (2010) 1.88
Urocortin inhibits Beclin1-mediated autophagic cell death in cardiac myocytes exposed to ischaemia/reperfusion injury. J Mol Cell Cardiol (2006) 1.83
Numerical scoring for the BILAG-2004 index. Rheumatology (Oxford) (2010) 1.83
STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J Biol Chem (2003) 1.79
Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology (2003) 1.76
British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum (2007) 1.74
Decreased Lyn expression and translocation to lipid raft signaling domains in B lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum (2005) 1.74
Urocortin prevents mitochondrial permeability transition in response to reperfusion injury indirectly by reducing oxidative stress. Am J Physiol Heart Circ Physiol (2007) 1.70
Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. J Rheumatol (2009) 1.67
A heterozygous effect for PINK1 mutations in Parkinson's disease? Ann Neurol (2006) 1.61
Normalizing glycosphingolipids restores function in CD4+ T cells from lupus patients. J Clin Invest (2014) 1.60
Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum (2010) 1.60
Activation of CDK4 gene expression in human breast cancer cells by the Brn-3b POU family transcription factor. Cancer Biol Ther (2004) 1.57
Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum (2006) 1.56
Arsenic exposure in pregnancy: a population-based study in Matlab, Bangladesh. J Health Popul Nutr (2006) 1.56
The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. Rheumatology (Oxford) (2011) 1.55
Enhanced IL-17 signalling following myocardial ischaemia/reperfusion injury. Int J Cardiol (2011) 1.52
Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. J Clin Invest (2004) 1.52
The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology (Oxford) (2009) 1.52
Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford) (2009) 1.50
Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun (2013) 1.47
Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). Rheumatology (Oxford) (2013) 1.46
The transcriptional co-activators CREB-binding protein (CBP) and p300 play a critical role in cardiac hypertrophy that is dependent on their histone acetyltransferase activity. J Biol Chem (2002) 1.45
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis (2014) 1.45
Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study. Arthritis Res Ther (2009) 1.44
STAT-1: a novel regulator of apoptosis. Int J Exp Pathol (2003) 1.43
B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis (2007) 1.42
The 52 000 MW Ro/SS-A autoantigen in Sjögren's syndrome/systemic lupus erythematosus (Ro52) is an interferon-gamma inducible tripartite motif protein associated with membrane proximal structures. Immunology (2002) 1.42
Systemic lupus erythematosus. Orphanet J Rare Dis (2006) 1.36
B-cell-depletion therapy in SLE--what are the current prospects for its acceptance? Nat Rev Rheumatol (2009) 1.35
Association of antenatal care with facility delivery and perinatal survival - a population-based study in Bangladesh. BMC Pregnancy Childbirth (2012) 1.34
Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. J Alzheimers Dis (2009) 1.34
PIAS-1 is a checkpoint regulator which affects exit from G1 and G2 by sumoylation of p73. Mol Cell Biol (2004) 1.33
Role of the JAK-STAT pathway in myocardial injury. Trends Mol Med (2006) 1.32
Antineutrophil cytoplasmic autoantibodies in systemic lupus erythematosus. Lupus (2003) 1.32
Epigallocatechin-3-gallate inhibits STAT-1 activation and protects cardiac myocytes from ischemia/reperfusion-induced apoptosis. FASEB J (2004) 1.31
The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford) (2011) 1.25
The neuroprotective effects of heat shock protein 27 overexpression in transgenic animals against kainate-induced seizures and hippocampal cell death. J Biol Chem (2003) 1.24
In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther (2006) 1.23
Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells. Immunity (2012) 1.21
Arsenic methylation efficiency increases during the first trimester of pregnancy independent of folate status. Reprod Toxicol (2010) 1.20
Different signaling pathways induce apoptosis in endothelial cells and cardiac myocytes during ischemia/reperfusion injury. Circ Res (2002) 1.18
Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β2-glycoprotein I. Arthritis Rheum (2011) 1.18
Population-based incidence and etiology of community-acquired neonatal bacteremia in Mirzapur, Bangladesh: an observational study. J Infect Dis (2009) 1.18
Effective delivery styles and content for self-management interventions for chronic musculoskeletal pain: a systematic literature review. Clin J Pain (2012) 1.17
Retracted STAT-1 facilitates the ATM activated checkpoint pathway following DNA damage. J Cell Sci (2005) 1.17
Nutritional status has marginal influence on the metabolism of inorganic arsenic in pregnant Bangladeshi women. Environ Health Perspect (2008) 1.16
Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology (Oxford) (2011) 1.15
BAG-1: a multi-functional pro-survival molecule. Int J Biochem Cell Biol (2005) 1.14
Respiratory manifestations of systemic lupus erythematosus: old and new concepts. Best Pract Res Clin Rheumatol (2009) 1.14
Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis? Arthritis Rheum (2004) 1.13
Syndromes and complications of interferon therapy. Curr Opin Rheumatol (2007) 1.13
Numerical scoring for the Classic BILAG index. Rheumatology (Oxford) (2009) 1.13
Home-based life saving skills in Matlab, Bangladesh: a process evaluation of a community-based maternal child health programme. Midwifery (2009) 1.12
Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum (2013) 1.12
Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis Rheum (2007) 1.12
Protective effects of heat shock protein 27 in a model of ALS occur in the early stages of disease progression. Neurobiol Dis (2007) 1.11
Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology (Oxford) (2013) 1.10
Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1. Biochem Biophys Res Commun (2003) 1.10
Natural killer T cells in families of patients with systemic lupus erythematosus: their possible role in regulation of IGG production. Arthritis Rheum (2007) 1.10
Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. Arthritis Rheum (2006) 1.09
Data-driven modeling reconciles kinetics of ERK phosphorylation, localization, and activity states. Mol Syst Biol (2014) 1.09
Activation of protein kinase B/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia/reoxygenation-induced cell death. J Mol Cell Cardiol (2002) 1.09
HSP27 but not HSP70 has a potent protective effect against alpha-synuclein-induced cell death in mammalian neuronal cells. J Neurochem (2004) 1.09
Targeted disruption of the protein kinase C epsilon gene abolishes the infarct size reduction that follows ischaemic preconditioning of isolated buffer-perfused mouse hearts. Cardiovasc Res (2002) 1.09
Rituximab as early therapy for pulmonary haemorrhage in systemic lupus erythematosus. Rheumatology (Oxford) (2009) 1.08